Zealand Pharma A/S (OTCMKTS:ZLDPF - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Zealand Pharma A/S in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will post earnings of $7.74 per share for the year. The consensus estimate for Zealand Pharma A/S's current full-year earnings is ($2.19) per share.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The business had revenue of $1.14 million for the quarter, compared to analysts' expectations of $248.61 million.
Separately, William Blair upgraded Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
Check Out Our Latest Report on Zealand Pharma A/S
Zealand Pharma A/S Price Performance
OTCMKTS:ZLDPF traded down $1.66 during trading hours on Thursday, reaching $74.13. The company had a trading volume of 155 shares, compared to its average volume of 917. The stock has a 50-day moving average of $66.15 and a two-hundred day moving average of $85.91. Zealand Pharma A/S has a one year low of $57.97 and a one year high of $141.74. The firm has a market capitalization of $5.26 billion, a PE ratio of -31.41 and a beta of 0.74. The company has a quick ratio of 35.49, a current ratio of 35.49 and a debt-to-equity ratio of 0.03.
Zealand Pharma A/S Company Profile
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Featured Articles
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
